Oncology

News

Can new Tukysa data drop unlock its sales potential?

A phase 3 study suggests Pfizer's underperforming HER2 inhibitor Tukysa could play a role in first-line maintenance of HER2-positive breast cancer.

News

Astellas suffers pancreatic cancer failure with Vyloy

Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.

Digital

Precision medicine meets machine learning: AI and oncology b...

A close examination of the current and future role of AI in biomarker discovery and the challenges that developers face in leveraging it.

News

Kelun gets world-first approval for TROP2 ADC

Kelun-Biotech has picked up another world-first approval for its TROP2-targeting ADC sac-TMT in non-small cell lung cancer.

News

Regeneron's Libtayo stakes out new territory in skin cancer

Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

Digital

Agentic AI buoys all stakeholders in oncology, with Eron Kel...

At LSX 2025, Eron Kelly, CEO of Concert AI, discussed the work his Boston-based start-up is doing in oncology.

Can new Tukysa data drop unlock its sales potential?

Astellas suffers pancreatic cancer failure with Vyloy

Precision medicine meets machine learning: AI and oncology b...

Kelun gets world-first approval for TROP2 ADC

Regeneron's Libtayo stakes out new territory in skin cancer

Agentic AI buoys all stakeholders in oncology, with Eron Kel...

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Oncology

Editor's Picks